MICHAEL ALBERT: Open Payments
NPI 1679562094 · RICHLAND, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$556 in 25 payments from 10 companies in 2025. Trend: 2023 $344 · 2024 $749 · 2025 $556
Food & beverage: $556
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $162 |
| Teva Pharmaceuticals USA, Inc. | 7 | $141 |
| Neurocrine BioSciences, Inc. | 2 | $60 |
| ABBVIE INC. | 1 | $44 |
| Lundbeck LLC | 1 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $26 |
| PFIZER INC. | 1 | $19 |
| Novo Nordisk Inc | 1 | $19 |
| Inari Medical, Inc. | 1 | $18 |
Products named: REXULTI, AUSTEDO XR, INGREZZA, DALVANCE, CAPLYTA, Kerendia, PAXLOVID, Ozempic.
Industry payments across MS — which companies pay providers there.
